Compare D R Horton Inc (DHI) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Enveric Biosciences Inc — how do they compare? D R Horton Inc trades at $150.79 (market cap $41.02B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: D R Horton Inc is far larger — about 6616.1× Enveric Biosciences Inc's market cap, and D R Horton Inc pays a 1.23% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| DHI | ENVB | |
|---|---|---|
Market Cap | $41.02B | $6.20M |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $17.40 |
52-Week Low | $132.53 | $1.27 |
Enterprise Value | $46.13B | $1.30M |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $151.08, up 3.47% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance amid persistent affordability pressures. Valuation metrics appear reasonable with a P/E of 14.4 and P/S of 1.32, while profitability remains solid with a net income margin of 9.15%.
The outlook is mixed: strong execution and cash returns provide support, but weaker demand and margin pressure pose headwinds. Investment opportunity lies in disciplined inventory management and shareholder returns, while risks include elevated mortgage rates and competitive threats from disruptors like Boxabl. Analyst sentiment is balanced with 45% buy ratings.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
